Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 January 2014Website:
http://www.glycomimetics.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:59:42 GMTDividend
Analysts recommendations
Institutional Ownership
GLYC Latest News
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC ), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company.
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating GlycoMimetics (NASDAQ: GLYC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crescent. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Under the agreement, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company and Crescent stockholders are expected to own approximately 96.9% o.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of GlycoMimetics, Inc. (NASDAQ: GLYC) and Crescent Biopharma, Inc. is fair to GlycoMimetics shareholders. Upon closing of the proposed transaction, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company. Halper Sadeh encourages GlycoMimetics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary.
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for inten.
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML). The event will feature the study'.
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Hahn - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - TD Cowen Operator Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.
GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and technical momentum indicators suggest a bullish outlook for the company's stock, currently trading at $1.85 per share. The drug has the potential to be used in combination therapies for various cancer treatments, but investors should consider the risks and only allocate a small portion of their portfolio to GlycoMimetics.
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and their loved ones.
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chief Executive Officer Brian Hahn - Chief Financial Officer Edwin Rock - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Operator Good morning. And thank you for joining the GlycoMimetics Fourth Quarter and Full Year 2022 Earnings Call.
What type of business is GlycoMimetics?
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
What sector is GlycoMimetics in?
GlycoMimetics is in the Healthcare sector
What industry is GlycoMimetics in?
GlycoMimetics is in the Biotechnology industry
What country is GlycoMimetics from?
GlycoMimetics is headquartered in United States
When did GlycoMimetics go public?
GlycoMimetics initial public offering (IPO) was on 10 January 2014
What is GlycoMimetics website?
https://www.glycomimetics.com
Is GlycoMimetics in the S&P 500?
No, GlycoMimetics is not included in the S&P 500 index
Is GlycoMimetics in the NASDAQ 100?
No, GlycoMimetics is not included in the NASDAQ 100 index
Is GlycoMimetics in the Dow Jones?
No, GlycoMimetics is not included in the Dow Jones index
When was GlycoMimetics the previous earnings report?
No data
When does GlycoMimetics earnings report?
The next expected earnings date for GlycoMimetics is 08 November 2024